Special Issue

DNA Damage and Repair in Cancer Risk Prediction

Message from the Guest Editors

Cancer is the most dreadful disease and one of the major obstacles in improving human life span worldwide. Because of its heterogenous nature, cancer displays altered genomic and epigenetic variations among patients. Conventional chemotherapeutics has been limited due to this heterogeneity, and patients develop resistance with severe side effects. Compelling evidence suggests the crucial role of DNA damage response and repair in multiple cancer types. Although cells are equipped with damage surveillance and repair machinery, failure to carry out this role leads to the accumulation of multiple types of DNA damage. The proliferation of these cells with unrepaired DNA causes genomic instability and strongly contributes to cancer. DNA damage repair-deficient cancer cells are often sensitive to DNA damage agents, making them a potential target for cancer therapy. In this Special Issue, we focus on recent advances in DNA damage repair in cancer prediction, working toward cancer as a curable disease.

Guest Editors

Dr. Mansoor Hussain
National Institute on Aging (NIA), Bethesda, MD, USA

Dr. Santhilal Subhash
Cold Spring Harbor Laboratory, New York, NY, USA

Dr. Tanushree Ghosh
Carnegie Science, Balitimore, MA, USA

Deadline for manuscript submissions

closed (30 September 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/153131

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)